Name | No. | For Patients with | Purpose |
---|---|---|---|
MK7902-002/E7080-G000-311/LEAP-002 | CTRIAL-IE 18-43 | This study will evaluate the safety and efficacy of lenvatinib alone or in combination with pembrolizumab as first-line intervention |
DSSG Group: Gastrointestinal
Astellas 8951-CL-5201
Name | No. | For Patients with | Purpose |
---|---|---|---|
Astellas 8951-CL-5201 | CTRIAL-IE 18-44 | Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) |
Paricalcitol Trial
Name | No. | For Patients with | Purpose |
---|---|---|---|
Paricalcitol Trial | 19-33 | Incurable recurrent, locally advanced or metastatic pancreatic adenocarcinoma. |
The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer. |
MK3475-966-00
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK3475-966-00 | 19-23 | 1L Advanced/Unresectable Biliary Tract Carcinoma |
The purpose of this study is to compare Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma |
FIDES-01 (Formerly ARQ 087-301)
Name | No. | For Patients with | Purpose |
---|---|---|---|
FIDES-01 (Formerly ARQ 087-301) | 18-10 | Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications. |
To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications. |
INCB 54828-302
Name | No. | For Patients with | Purpose |
---|---|---|---|
INCB 54828-302 | 18-45 | Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement |
The purpose of this trial is to evaluate the efficacy of pemigatinib versus standard chemotherapy in the first-line treatment of patients with Unresectable or Metastatic Cholangiocarcinoma, whos tumors harbor FGFR2 gene rearrangement. |
MK3475-937 (KEYNOTE-937)
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK3475-937 (KEYNOTE-937) | 19-07 | Hepatocellular Carcinoma |
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937). |
SOLSTICE
Name | No. | For Patients with | Purpose |
---|---|---|---|
SOLSTICE | CTRIAL-IE 19-08 | Metastatic colorectal cancer (bowel cancer) that is unresectable and not suitable for intensive therapy |
The main purpose of the study is to determine if S95005 in combination with bevacizumab is better than capecitabine with bevacizumab for progression free survival in mCRC patients who have not received any treatment for metastatic disease yet and are not suitable for intensive chemotherapy |
KEYNOTE-859 (MK3475-859)
Name | No. | For Patients with | Purpose |
---|---|---|---|
KEYNOTE-859 (MK3475-859) | 18-30 | Previously untreated HER2 negative advanced cancer of the stomach or the junction between the stomach and the oesophagus (gastrooesophageal junction). |
This trial will compare the effectiveness of a drug called Pembrolizumab used in combination with chemotherapy, to a placebo used in combination with chemotherapy. Patients will be randomly assigned (randomised) between either Pembrolizumab and chemotherapy, or placebo and chemotherapy. |